NCT05636514 2026-03-18
CELESTIAL-MDS
Clinical Hub for Interventional Research (CHOIR)
Phase 1 Recruiting
Clinical Trials
17 trialsNCT06072781 2026-03-17
RAMP 301
Verastem, Inc.
Phase 3 Recruiting
NCT03875820 2026-03-10
FRAME
Institute of Cancer Research, United Kingdom
Phase 1 Active not recruiting
NCT06007924 2026-02-19
A Study of Avutometinib and Defactinib in People With Thyroid Cancer
Memorial Sloan Kettering Cancer Center
Phase 2 Recruiting
NCT04331041 2026-02-17
Stereotactic Body Radiotherapy and Focal Adhesion Kinase Inhibitor in Advanced Pancreas Adenocarcinoma
Washington University School of Medicine
Phase 2 Active not recruiting
NCT06369259 2026-02-11
Open-label Phase 2 Study of Avutometinib (RAF/MEK Clamp) in Combination With Defactinib (FAK Inhibitor) and Cetuximab in Patients With Unresectable, Anti-EGFR-Refractory Advanced Colorectal Cancer
M.D. Anderson Cancer Center
Phase 2 Recruiting
NCT03727880 2026-02-04
Study of Pembrolizumab With or Without Defactinib Following Chemotherapy as a Neoadjuvant and Adjuvant Treatment for Resectable Pancreatic Ductal Adenocarcinoma
The University of Texas Health Science Center at San Antonio
Phase 2 Completed
NCT06394804 2026-02-03
CHAMELEON
Memorial Sloan Kettering Cancer Center
Phase 2 Recruiting
NCT06630260 2026-01-21
5G-RUBY
Institute of Cancer Research, United Kingdom
Phase 1/2 Recruiting
NCT07318324 2026-01-06
Phase Ib Study of Avutometinib, Defactinib, and Everolimus in RAS Pathway Mutant Endometrial Cancer
M.D. Anderson Cancer Center
Phase 1 Not yet recruiting
NCT07126158 2026-01-05
Stereotactic Body Radiotherapy Plus FAK and RAF/MEK Inhibition in Advanced Pancreatic Adenocarcinoma
Washington University School of Medicine
Phase 2 Not yet recruiting
NCT06682572 2025-12-17
RAMP201J
Verastem, Inc.
Phase 2 Active not recruiting
NCT05798507 2025-12-15
Identification of Treatment Concentrations of Defactinib or VS-6766 for the Treatment of Patients With Glioblastoma
Emory University
Phase EARLY_PHASE1 Active not recruiting
NCT06194929 2025-12-03
DETERMINE
University of Utah
Phase 1/2 Recruiting
NCT05512208 2025-10-22
DURAFAK
University of Oklahoma
Phase 2 Recruiting
NCT05669482 2025-09-02
RAMP205
Verastem, Inc.
Phase 1/2 Active not recruiting
NCT06495125 2025-04-17
Defactinib, Avutometinib and Nivolumab for the Treatment of Anti-PD1 Refractory LKB1-Mutant Advanced Non-Small Cell Lung Cancer
Emory University
Phase 2 Recruiting